In lung cancer, the use of EGFR tyrosine kinase inhibitors (EGFR-TKIs) is now a common practice for the first-line treatment of patients with EGFR sensitizing mutation, leading to longer progression-free survival (PFS) intervals with fewer or at least different side effects than chemotherapy (12). The gene discussed is EGFR; the disease is lung cancer.